CRISPR-based gene editing shows promise in treating rare form of blindness

FHS
May 6, 2024
6:43 pm

About 79% of clinical trial participants experienced measurable improvement after receiving experimental, CRISPR-based gene editing that is designed to fix a rare form of blindness, according to a paper published in the New England Journal of Medicine.

The Quintuple Aim: Redefining Patient-Centered Care in the Digital Age

Prashila Dullabh, VP & Senior Fellow, Health Sciences and Director, Health Implementation Science Center at NORC at the University of Chicago Patient-centered care is constantly

January 17, 2025

Study reports the first local case of mpox caused by imported case in the Chinese mainland

Monkeypox (mpox) is a zoonotic disease caused by the mpox virus (MPXV) that has been primarily limited to Central and West African nations since its

July 18, 2023

Biotech Bonanza 2023 Biotech OutlookAs The FED Remains Hawkish • Prudent Biotech

Federal Reserve interest rate policy to again remain the market focus this year and create a chaotic first half. Biotechs should be favorably positioned relative

January 10, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.